[1]Ding Y, Duan S, Ye R, et al. Effects of aging, baseline renal function and stage of HIV infection on posttreatment changes in renal function among HIVinfected patients: a retrospective cohort study[J]. HIV Med, 2019, 20(9): 591-600.
[2]何纳. 中国艾滋病流行病学研究新进展[J]. 中华疾病控制杂志, 2021, 25(12): 1365-1368.
[3]Govender RD, Hashim MJ, Khan MA, et al. Global epidemiology of HIV/AIDS: a resurgence in North America and Europe[J]. J Epidemiol Glob Health, 2021, 11(3): 296-301.
[4]中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中国艾滋病性病, 2021, 27(11): 1182-1201.
[5]俊梅. 艾滋病的流行情况和危险因素与预防进展[J]. 中国城乡企业卫生, 2021, 36(1): 43-45.
[6]Cao W, Hsieh E, Li T. Optimizing treatment for adults with HIV/AIDS in China: successes over two decades and remaining challenges[J]. Curr HIV/AIDS Rep, 2020, 17(1): 26-34.
[7]田云飞, 肖江, 韩宁, 等. HIV/AIDS患者免疫重建不良的研究进展[J]. 中华实验和临床感染病杂志, 2015, 9(4): 462-467.
[8]Shete A, Dhayarkar S, Sangale S, et al. Incomplete functional Tcell reconstitution in immunological nonresponders at one year after initiation of antiretroviral therapy possibly predisposes them to infectious diseases[J]. Int J Infect Dis, 2019, 81: 114-122.
[9]Yang X, Su B, Zhang X, et al. Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: Challenges of immunological nonresponders[J]. J Leukoc Biol, 2020, 107(4): 597-612.
[10]Blanco JR, Alejos B, Moreno S. Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING2)[J]. PLoS One, 2020, 15(1): e0226724.
[11]Bayarsaikhan S, Jagdagsuren D, Gunchin B, et al. Survival, CD4 T lymphocyte count recovery and immune reconstitution pattern during the firstline combination antiretroviral therapy in patients with HIV1 infection in Mongolia[J]. PLoS One, 2021, 16(3): e0247929.
[12]Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1infected individuals receiving potent antiretroviral therapy[J]. Clin Infect Dis, 2005, 41(3): 361-372.
[13]Stiksrud B, Aass HCD, Lorvik KB, et al. Activated dendritic cells and monocytes in HIV immunological nonresponders: HIVinduced interferoninducible protein10 correlates with low future CD4+ recovery[J]. AIDS, 2019, 33(7): 1117-1129.
[14]中华中医药学会防治艾滋病分会. 艾滋病免疫功能重建不良中西医协同治疗专家共识[J]. 中医学报, 2020, 35(2): 281-284.
[15]Mohamad Isa II, Abu Bakar S, Ab Rahman AK. Ethnicity as predictor of immune reconstitution among Malaysian HIVpositive patients treated with highly active antiretroviral therapy[J]. J Med Virol, 2020, 92(8): 1173-1181.
[16]Negash H, Legese H, Tefera M, et al. The effect of tuberculosis on immune reconstitution among HIV patients on highly active antiretroviral therapy in Adigrat general hospital, eastern Tigrai, Ethiopia; 2019: a retrospective follow up study[J]. BMC Immunol, 2019, 20(1): 45.
[17]Kroeze S, Ondoa P, Kityo CM, et al. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in subSaharan Africa[J]. AIDS, 2018, 32(8): 1043-1051.
[18]Zicari S, Sessa L, Cotugno N, et al. Immune activation, inflammation, and nonAIDS comorbidities in HIVinfected patients under longterm ART[J]. Viruses, 2019, 11(3): 200.
[19]de Paula HHS, Ferreira ACG, Caetano DG, et al. Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in early chronic HIV1 infection[J]. Retrovirology, 2018, 15(1): 76.
[20]Li X, Ding H, Geng W, et al. Predictive effects of body mass index on immune reconstitution among HIVinfected HAART users in China[J]. BMC Infect Dis, 2019, 19(1): 373.
[21]Han WM, Jiamsakul A, Jantarapakde J, et al. Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV[J]. HIV Med, 2021, 22(4): 294-306.
[22]张驰宇, 许燕萍, 贲昆龙. HIV1感染对T和B细胞核内UNG2 mRNA表达的影响[J].江苏大学学报(医 学版), 2007, 17(1): 5-8.
[23]李超锋, 杨萱, 杨晓霞, 等. 郑州市HIV/AIDS病人一线抗病毒治疗失败发生规律及影响因素分析[J]. 中国艾滋病性病, 2019, 25(3): 239-242.
[24]Roul H, MaryKrause M, Ghosn J, et al. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era[J]. AIDS, 2018, 32(17): 2605-2614.
[25]刘晓霞, 张明辉, 叶鲁, 等. 2005—2015年镇江市HIV/AIDS抗病毒治疗效果及影响因素[J]. 江苏预防医学, 2018, 29(5): 491-493.
[26]陈晨, 钟明丽, 成骢, 等. 南京地区HIV/AIDS患者一线抗病毒治疗失败相关因素分析[J]. 江苏大学学报(医学版), 2021, 31(6): 506-510.
[27]周成林, 杨启生, 殷竹娟, 等. HIV感染者血清IL1α、IL7、IL12和IL15水平的变化及意义[J]. 江苏大学学报(医学版), 2012, 22(3): 275-276.
[28]Bloch M, John M, Smith D, et al. Managing HIVassociated inflammation and ageing in the era of modern ART[J]. HIV Med, 2020, Suppl 3: 2-16.
[29]Jiang TY, Hou JH, Su B, et al. Demographic and clinical factors associated with immune reconstitution in HIV/HBV coinfected and HIV monoinfected patients: a retrospective cohort study[J]. HIV Med, 2020, 21(11): 722-728.
[30]Chen S, Han Y, Song XJ, et al. Very high baseline HIV viremia impairs efficacy of nonnucleoside reverse transcriptase inhibitorbased ART: a longterm observation in treatmentnave patients[J]. Infect Dis Poverty, 2020, 9(1): 75.
[31]Chehimi J, Azzoni L, Farabaugh M, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV1infected subjects undergoing antiretroviral treatment[J]. J Immunol, 2007, 179(4): 2642-2650.
[32]Li K, Chen H, Li J, et al. Immune reconstruction effectiveness of combination antiretroviral therapy for HIV1 CRF01_AE cluster 1 and 2 infected individuals[J]. Emerg Microbes Infect, 2022, 11(1): 158-167.
[33]Martin DA, Luz PM, Lake JE, et al. Improved virologic outcomes over time for HIVinfected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997—2011[J]. BMC Infect Dis, 2014, 14: 322.
[34]Wijting IEA, Wit FWNM, Rokx C, et al. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy[J]. E Clinical Medicine, 2019, 17: 100210.
[35]Tanuma J, Matsumoto S, Haneuse S, et al. Longterm viral suppression and immune recovery during firstline antiretroviral therapy: a study of an HIVinfected adult cohort in Hanoi, Vietnam[J]. J Int AIDS, 2017, 20(4): e25030.
[36]Chen J, Titanji K, Sheth AN, et al. The effect of age on CD4+ Tcell recovery in HIVsuppressed adult participants: a substudy from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study[J]. Immun Ageing, 2022, 19(1): 4.
[37]Abraham AG, Zhang L, Calkins K, et al. Vitamin D status and immune function reconstitution in HIVinfected men initiating therapy[J]. AIDS, 2018, 32(8): 1069-1076.